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Highlights 
 Hypovitaminosis D is common in the haemodialysis (HD) population in Coventry. 
 There is an absence of clear supplementation guidelines for this population. 
 We have developed a local guideline for vitamin D supplementation in HD 
patients. 
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Abstract 
Low serum 25(OH)D and associated bone and non-bone related problems are not well 
appreciated in end stage renal disease (ESRD). Vitamin D treatment strategies in the UK 
currently focus almost exclusively on calcitriol [1,25(OH)2D], alfacalcidol or paricalcitol. In 
ESRD hypovitaminosis D is associated with bone loss, muscle weakness, falls, fractures and 
increased inflammation. National guidelines changed in 2014 and now recommend the 
diagnosis and treatment of low serum 25(OH)D in all patients with glomerular filtration rate 
(GFR) less than 30ml/min/1.73m2. However as yet there are no standardized guidelines for 
dosage, frequency and monitoring in ESRD patients. Following a systematic review of the 
literature we developed a clinical guideline for cholecalciferol supplementation at University 
Hospitals of Coventry and Warwickshire, UK. The guideline recommends 40,000IU 
cholecalciferol weekly for patients with 25(OH)D <50nmol/L and 20,000IU weekly for patients 
with 25(OH)D 50-75nmol/L; to be continued long term unless levels increase to ≥150nmol/L. 
To date we have measured 25(OH)D levels in 385 in-center haemodialysis patients. Virtually 
all patients (95%) had serum 25(OH)D levels <75nmol/L (65% deficient, <30nmol/L; 30% 
insufficient, 30-74nmol/L). Only 5% of patients had optimal levels (≥75nmol/L). Our data 
indicates that hypovitaminosis D is prevalent in the haemodialysis population in Coventry 
and Warwickshire and this is likely to reflect UK haemodialysis patients, highlighting the 
need for a national supplementation guideline. 
 
Keywords: vitamin D; hypovitaminosis D; cholecalciferol; ESRD; haemodialysis; 25 
hydroxyvitamin D 
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1. Introduction 
End stage renal disease (ESRD) is characterised by decreased renal expression of 25-
hydroxyvitamin D 1α-hydroxylase (CYP27B1; 1α-OHase), the enzyme that catalyses the 
conversion of 25-hydroxyvitamin D (25(OH)D) the form synthesised in the liver by 25-
hydroxylase following production of vitamin D in the skin, to the active form, 1,25-
dihydroxyvitamin D (1,25(OH)2D). This is well appreciated in the clinical setting and the 
majority of haemodialysis patients require treatment with an active vitamin D or an analogue 
(calcitriol, alfacalcidol or paricalcitol) for the management of calcium and secondary 
hyperparathyroidism.1,2 However, recent data have shown that ESRD patients also have low 
serum 25(OH)D levels with vitamin D deficiency and insufficiency (serum 25(OH)D 
<30nmol/l and <75nmol/l respectively) seen in up to 95% of haemodialysis patients.3,4 This is 
attributed to reduced sunlight exposure, an ethnically diverse and ageing population; both of 
which have implications on skin synthesis of vitamin D, and the uremic state which hinders 
hydroxylation of vitamin D in the liver.5 Anecdotal evidence suggests concurrent 
cholecalciferol treatment to optimise serum 25(OH)D levels may result in further 
improvement in mineral bone markers6. Non-classical extra-skeletal benefits of 25(OH)D in 
ESRD are less clear, but recent studies suggest vitamin D deficiency may be associated 
with resistance to erythropoietin (EPO), reduced health-related quality of life (HRQOL), and 
increased levels of inflammation and infection.7-14 
UK guidelines changed in 2014 and now recommend the diagnosis and treatment of low 
serum 25(OH)D in all people with a glomerular filtration rate (GFR) less than 
30ml/min/1.73m2 however they make no recommendations for dosage or monitoring and as 
such recommendations have not widely translated into practice.15 This, along with a poor 
understanding of the physiological roles of vitamin D beyond bone mineral homeostasis and 
a misconception that 1,25(OH)2D therapy alone is sufficient, has meant hypovitaminosis D in 
ESRD remains prevalent. 
The aims of this study were to assess the extent of vitamin D insufficiency/deficiency in the 
haemodialysis population of Coventry and Warwickshire, and to develop a clinical guideline 
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for cholecalciferol supplementation in haemodialysis patients at the University Hospitals of 
Coventry and Warwickshire (UHCW) in order to replete serum 25(OH)D levels to ≥75nmol/L 
in ≥90% patients. 
 
2. Methods 
2.1 Guideline development 
A structured review of the current literature looking at the safety and efficacy of 
cholecalciferol supplementation in haemodialysis patients was completed. Search strategy 
was defined by the question; what dose of cholecalciferol is required to replete 
haemodialysis patients serum 25(OH)D levels to ≥75nmol/l? The optimal level of 75nmol/L 
was chosen based on the Endocrinology Society guidelines.16 Between February and June 
2014 the following databases were searched; Embase, Medline, Web of Science, Cochrane, 
Cinahl and Proquest. The following search terms were used; (i) for intervention; Dietary 
Supplements/supplement*, drug therapy, vitamin D, vitamin D deficiency, cholecalciferol,  
colecalciferol, (ii) for population; haemodialysis, haemodialysis, renal dialysis, kidney failure, 
chronic kidney disease, esrd, end stage renal disease, end stage renal failure, renal 
insufficiency, (iii) criteria for paper; ‘limit to English’. Search results were screened by two 
reviewers (SH and RB) according to preset inclusion and exclusion criteria; initially by title, 
then by abstract, and finally by full article (reported in section 3.1 and figure 1). 
 
2.2 Patient recruitment 
Routine screening of serum 25(OH)D in all patients having in-center haemodialysis at 
UHCW NHS trust was introduced from November 2014. If required cholecalciferol is 
prescribed by the patient's renal consultant within their dialysis prescription book and 
administration is overseen by nursing staff. Cholecalciferol (Fultium D3) is given according to 
the guideline outlined in section 3.1 and table 1. NHS ethical approval to study the efficacy 
and effects of cholecalciferol supplementation was obtained. 
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2.3 Serum 25(OH)D analysis 
Serum 25(OH)D levels were measured in routinely collected blood samples by the hospital 
biochemistry laboratories using Elecsys Vitamin D Total Assay (Roche). The percentage 
coefficient of variation varied according to mean serum level and were; 13.6% for 
10.2nmol/L, 9.1% for 33.5nmol/L and 6.3% for 73.8nmol/L. 
 
3. Results 
3.1 Cholecalciferol supplementation guideline 
A flow diagram of the literature identification process is shown in figure 1. The combined 
search of Embase, Medline, Web of Science, Cochrane, Cinahl and Proquest identified 2847 
citations. 2816 were excluded after title and abstract review. Full text assessment of 34 
articles identified 17 papers which were reviewed. Although search parameters were not 
limited by year, these papers were published between 2008 and 2014. Studies varied in the 
number of participants (7-158), length of study intervention (3-104 weeks) and cholecalciferol 
dose (weekly equivalent 5,000-100,000IU). The average baseline 25(OH)D level was 
<50nmol/L in all but one study. Only two studies were carried out over 24 months however 
adequate repletion was only achieved in 9.2% and 57% of patients.17,4 Although fourteen 
studies reported average repletion of 25(OH)D to >75nmol/L, repletion of ≥90% of the 
population was only achieved in 7 of these.6,18-23 While these studies varied in 
supplementation dose and duration, in 6/7 studies the minimum weekly dose of 
cholecalciferol was 20,000IU for ≥8 weeks. In the remaining study patients were given 
200,000IU a week for 3 weeks.23 Of the combined study population receiving cholecalciferol 
(n=239) and throughout the duration of these 7 studies only 6 incidents of hypercalcaemia 
were reported and in many cases patients were receiving concurrent active vitamin D 
analogue treatment. 
The guideline was developed by the renal multidisciplinary team consisting of dietitians, 
renal consultants and specialist renal pharmacist, and a summary of the information from the 
review was discussed with two vitamin D experts. Based on the review data and taking 
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account of local clinical guidelines for the general population the guideline we developed for 
haemodialysis patients (table 1) recommends 40,000IU cholecalciferol weekly for patients 
with 25(OH)D <50nmol/L (to be reviewed at 3 months) and 20,000IU weekly for patients with 
25(OH)D 50-75nmol/L; to be continued long term unless levels increase to ≥150nmol/L. If 
levels increase to ≥150nmol/L cholecalciferol should be stopped and 25(OH)D levels 
rechecked in 3 months. Although cholecalciferol supplementation is considered safe, 
hypercalcaemia is considered a marker of toxicity and as such must be monitored. Serum 
calcium is routinely measured each month in haemodialysis patients and should be 
maintained between 2.10-2.58mmol/L (based on the local laboratory reference range and 
corrected for serum albumin). If hypercalcaemia occurs the following calcium therapies 
should be reviewed; calcium supplements, calcium based phosphate binders, alfacalcidol, 
calcitriol and paricalcitol. Where required calcium therapies should be discontinued. 
Cholecalciferol should not be discontinued unless hypercalcaemia remains after the above 
calcium therapies are stopped. In the event that cholecalciferol needs to be discontinued the 
patients’ vitamin D level should be checked in order to assess for toxicity. Serum intact 
parathyroid hormone should be maintained at 8-38pmol/L (2-9 times the upper laboratory 
target). Cholecalciferol should be given concurrently with current treatment regimens for 
hyperparathyroidism; as per by current UHCW and NICE (National Institute for Health and 
Care Excellence) guidance2. 
 
3.2 Prevalence of hypovitaminosis D 
To date we have measured serum 25(OH)D levels in 385 haemodialysis patients. Virtually 
all patients (95%) had serum 25D levels <75nmol/L (65% deficient, <30nmol/L; 30% 
insufficient, 30-74nmol/L). Only 21 patients (5%) had optimal levels (≥75nmol/L) (figure 2). 
 
4. Discussion 
Data from this study supports other studies that suggest hypovitaminosis D is common in the 
haemodialysis population. Deficiency is multifactorial and in addition to the issues highlighted 
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earlier, increased 24-hydroxylase activity (induced by the use of active vitamin D analogues) 
and increased levels of FGF23 (fibroblast growth factor 23) seen in ESRD, could also be 
key. 
We have produced a local guideline to ensure deficiency is identified and appropriately 
treated in our patients. Serum 25(OH)D levels are measured initially every 3-4 months in all 
haemodialysis patients at UHCW (to enable monitoring of effectiveness, safety and 
adherence), but this will be reviewed in the longer term once the efficacy and maintenance 
data over an 18 month prospective period has been appraised. Whilst the maintenance dose 
of cholecalciferol recommended in our guideline (20,000IU weekly) is higher than the current 
national guidelines recommend for the general population24 it is well within the 
recommended safe upper limits.25,26 The sample size of our haemodialysis cohort (n=385) is 
unmatched by any comparable previous or currently ongoing research. This provides a 
unique opportunity, not only to collect repletion data, but also to collect biochemical and 
qualitative data in order to investigate classical and non-classical effects of vitamin D; 
something that can only be studied in the ESRD population, due to the reduced renal 
synthesis of 1,25(OH)2D. Currently an optimal serum 25(OH)D level remains controversial; 
we anticipate that our current and future studies together with other emerging evidence will 
help better determine a target serum 25(OH)D in relation to health outcomes in the 
haemodialysis population. 
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Figure Captions 
 
Figure 1. Flow diagram of literature identification process. Details of the number of citations 
identified and excluded at each stage of the search process are indicated. Search strategy 
was defined by the question; what dose of cholecalciferol is required to replete 
haemodialysis patients serum 25(OH)D levels to ≥75nmol/l. The following search terms were 
used; (i) for intervention; Dietary Supplements/supplement*, drug therapy, vitamin D, vitamin 
D deficiency, cholecalciferol,  colecalciferol, (ii) for population; haemodialysis, haemodialysis, 
renal dialysis, kidney failure, chronic kidney disease, esrd, end stage renal disease, end 
stage renal failure, renal insufficiency, (iii) criteria for paper; ‘limit to English’. Search results 
were screened by two reviewers (SH and RB) according to preset inclusion and exclusion 
criteria; initially by title, then by abstract, and finally by full article. 
 
Figure 2. Prevalence of hypovitaminosis D in haemodialysis patients Graph illustrating the 
serum 25(OH)D concentrations of 385 haemodialysis patients screened at University 
Hospitals of Coventry and Warwickshire (UK). Virtually all patients (95%) had serum 25D 
levels <75nmol/L (65% deficient, <30nmol/L; 30% insufficient, 30-74nmol/L). Only 21 
patients (5%) had optimal levels (≥75nmol/L). Data represents individual patient values 
grouped into deficient (<30nmol/L), insufficient (30-74nmol/L) and optimal (≥75nmol/L) 
(median). 
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Tables 
Table 1. Clinical guideline for cholecalciferol supplementation in haemodialysis patients at 
University Hospitals of Coventry and Warwickshire, UK. 
Serum 25(OH)D Cholecalciferol Dose 
<50nmol/L 40,000IU weekly. Review at 3 months. 
50-74nmol/L 20,000IU weekly. Review at 3 months. 
75-150nmol/L 
If not already taking cholecalciferol - no indication to start. 
If taking cholecalciferol already maintain levels on maintenance dose 
of 20,000IU weekly. Review at 3 months.
<150nmol/L STOP cholecalciferol, recheck level in 3 months and provided <150nmol/L restart maintenance dose of 20,000IU weekly.  
 
